The Effects of Tetramethylpyrazine on the Incidence of Arrhythmias and the Release of PGI2 and TXA2 in the Ischemic Rat Heart

Jun Feng; Guozhen Wu; Shuben Tang

doi:10.1055/s-2006-960774

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000058.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Planta Med 1999; 65(3): 268-270
DOI: 10.1055/s-2006-960774

Letter

The Effects of Tetramethylpyrazine on the Incidence of Arrhythmias and the Release of PGI₂ and TXA₂ in the Ischemic Rat Heart

Jun Feng¹ , Guozhen Wu¹ , Shuben Tang²

¹Department of Thoracic and Cardiovascular Surgery, First Teaching Hospital, Henan Medical University, Zhengzhou, P.R. China
²Department of Physiology, Henan Medical University, Zhengzhou, P.R. China

Further Information

Publication History

1998

1998

Publication Date:
04 January 2007 (online)

PDF Download Permissions and Reprints

Abstract

Pretreatment with tetramethylpyrazine (TMP, 12 mg/kg/day), a drug originally derived from the rhizomes of Ligusticum wallichii, significantly reduced the incidence of ischemia-induced ventricular tachycardia (VT) and fibrillation (VF) from 100% and 50% of control hearts to 41% (p < 0.05) and 0% (p < 0.05), respectively, in the ischemic rat heart. TMP also diminished the incidence of reperfusion-induced VT and VF from 100% and 100% of control hearts to 33% (p < 0.05) and 41% (p < 0.05), respectively. Pretreatment with TMP produced a slight, but significant increase of 6-keto-PGF_1α and a decrease of TXB₂ production during aerobic perfusion. Ischemia and reperfusion markedly increased the release of 6-keto-PGF_1α and TXB₂. Pretreatment with TMP significantly enhanced the release of 6-keto-PGF_1α and diminished TXB₂ outflow following left coronary artery occlusion and reperfusion.

>